Foster City, Calif., February 1, 2022 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has reached a global resolution with ViiV Healthcare for all pending or potential claims related to Gilead’s sales of the HIV treatment Biktarvy® (bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg tablets). Under the terms of the settlement agreement, ViiV Healthcare will dismiss all pending lawsuits relating to bictegravir, the novel compound in Biktarvy. Gilead will make a one-time payment of $1.25 billion and an ongoing royalty payment of 3% until 2027 on future sales of Biktarvy and on the bictegravir component of any future bictegravir-containing products sold in the U.S.
About Biktarvy
In the United States, Biktarvy is indicated as a complete single-tablet regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 14 kg who are new to antiretroviral (ARV) treatment or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of Biktarvy. In October 2021, the U.S. FDA approved a low-dose tablet formulation of Biktarvy (bictegravir 30 mg, emtricitabine 120 mg, and tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg. Biktarvy does not cure HIV-1 or AIDS.
SEE ALSO:
Source : Gilead Sciences, Inc.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.